I don't believe they have scheduled any clinical trials for DT010709 (mGluR3) yet. Kiwi, I'm not sure where you saw they are scheduled for a Phase II next year. To date, they only have reported on in vitro and in vivo studies. I would imagine that they would have to do a Phase I first. Don't confuse this drug with their related PD drug PXT002331, which is set to begin a Phase II trial next year. The research on DT010709 and another compound, DT011088 in 2011 and was funded by several MJFF grants. However, they hadn't been able to find a partner to move forward, until yesterday's announcement.